Silo Pharma Inc SILO 深 沪
已收盘 02-06 16:00:00 美东时间
0.3058
+0.019
+6.55%
华盛通- 最 高0.3281
- 今 开0.297
- 成交量 9.43万股
- 最 低 0.295
- 昨 收 0.287
- 总市值 407.27万
- 52周最高 1.5195
- 市盈率 静 --
- 换手率 0.71%
- 52周最低 0.2705
- 委 比 -33.33%
- 总股本 1331.83万
- 历史最高 7.26
- 量 比 0.58
- 振 幅 11.53%
- 历史最低 0.2705
- 每 手 1
- 风险率 0.34%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Silo Pharma Signs Non-Binding Letter Of Intent With Allucent To Offer Clinical Research Services For Two Phase 1 Trials Of SPC-15 Nasal Spray
Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a diversified developmental stage biopharmaceutical and cryptocurrency treasury company focused on developing novel formulations and drug delivery systems for
2025-12-30 21:07
Silo Pharma Selects Alphaledger’s T12 Fund for Tokenized Real-World Asset Investments on Solana Blockchain
Silo Pharma has selected the Alphaledger T12 Fund as a core component of its real-world asset investment strategy. The fund provides diversified access to tokenized assets on the Solana blockchain, offering high monthly income through alternative income-generating strategies while managing risk. Eric Weisblum, CEO of Silo, emphasized the fund's ability to reduce portfolio volatility and bridge traditional finance with digital assets. The partners...
2025-10-29 12:25
Silo Pharma Provides Update On Lead PTSD Candidate, SPC-15, Highlighting Safety And Toxicology Results, Ind-Enabling Studies, And Expanded Patents In The U.S., Australia, And Japan. Company Also Launched A Digital Assets Treasury In August 2025, Acquiring Bitcoin, Ethereum, Solana, And ResearchCoin
Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or "the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced a comprehensive update detailing progress for lead
2025-10-23 21:04
Silo Pharma Issues Update on Milestone Achievements in PTSD Drug Development and New Digital Assets Treasury Program
Silo Pharma announced advancements in its lead drug candidate, SPC-15, for PTSD and stress-induced anxiety, including positive safety data and IND application preparations. The company also expanded its digital asset treasury with purchases of Bitcoin, Ethereum, Solana, and ResearchCoin, supported by a new advisory board and Fireblocks infrastructure. CEO Eric Weisblum highlighted the company's strategic diversification to strengthen capital and ...
2025-10-23 12:45
Silo Pharma Expands Crypto Treasury with First Strategic Bitcoin Purchase Reinforcing Company’s Commitment to Multi-Chain Growth
Silo Pharma Inc. announced its initial Bitcoin purchase as part of its crypto reserve strategy targeting multi-chain asset growth. CEO Eric Weisblum highlighted the company's confidence in Bitcoin as a store of value and hedge against financial market volatility. This purchase follows previous investments in Ethereum, RSC, and Solano tokens, with plans to continue diversifying its crypto portfolio. Silo Pharma, a biopharmaceutical and cryptocurre...
2025-10-08 12:45
Silo Pharma acquires ResearchCoin crypto tokens
Silo Pharma (NASDAQ:SILO) on Monday announced its initial purchase of ResearchCoin (RSC) as part of its expanded digital assets treasury strategy. RSC is the native token of ResearchHub, a decentraliz...
2025-10-06 22:26
Silo Pharma Acquires ResearchCoin (RSC) Crypto Tokens in Support of Decentralized Science (DeSci)
<p>Silo Pharma announced its purchase of ResearchCoin (RSC), the native token of ResearchHub, a decentralized science platform co-founded by Coinbase CEO Brian Armstrong. This investment aligns with Silo's strategy to capture long-term value in emerging blockchain opportunities and support DeSci, a Web3 movement leveraging blockchain technologies to advance scientific collaboration and token-based economics. The purchase also reflects Silo's comm...
2025-10-06 12:10
Silo Pharma shares are trading lower after the company announced a $2.5M registered direct offering priced at-the-market under Nasdaq rules.
Silo Pharma shares are trading lower after the company announced a $2.5M regist...
2025-09-30 20:16
Silo Pharma Announces $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Silo Pharma has completed a registered direct offering, selling 2,857,143 shares at $0.875 per share and issuing warrants for the same number of shares at $0.75, raising approximately $2.5 million. Proceeds will support working capital and general corporate purposes. The offering is led by H.C. Wainwright as placement agent. The company focuses on innovative therapies for underserved conditions like PTSD, chronic pain, and CNS disorders.
2025-09-30 12:02
EXCLUSIVE: Silo Pharma Partners With Fireblocks To Advance Crypto Treasury Strategy Acquisition And Security
Silo Pharma partners with Fireblocks to secure its crypto treasury platform using multi-layer enterprise security and governance standards.
2025-09-23 20:16
